Pakkenberg H, Jensen I
Adv Neurol. 1983;37:151-7.
Two alpha-aminoergolines with different dopaminergic effects in rats were tried in two groups of Parkinson patients. CQ 32-084 was given in increasing doses up to 10 mg a day for 4 weeks to 10 Parkinson patients, 6 untreated cases and 4 cases with long-term levodopa treatment problems. The patients were checked every week by the Webster rating scale. All patients improved more or less, the earlier untreated patients more than the levodopa-treated patients. Most patients stopped at a dose of 15 mg a day. The side effects were slight. Another group of 10 patients with long-term levodopa treatment problems or insufficient effect of actual treatment were treated in a double-blind crossover trial with another ergoline derivative, CU 32-085. The dose was increased as in the first experiment up to 20 mg a day. Seven of the patients improved during the active drug period. In three cases, the hyperkinesia was increased during the active period, and in two cases it improved. Three patients found an obvious antidepressive effect during the active drug period. Five patients indicated slight decrease of on/off phenomena during the active period of treatment. A more extensive examination of these drugs seems indicated.
在两组帕金森病患者中试用了两种对大鼠具有不同多巴胺能效应的α-氨基麦角灵。对10例帕金森病患者、6例未经治疗的病例以及4例长期左旋多巴治疗存在问题的病例，给予CQ 32 - 084，剂量逐渐增加至每日10毫克，持续4周。每周用韦伯斯特评分量表对患者进行检查。所有患者或多或少都有改善，早期未经治疗的患者比接受左旋多巴治疗的患者改善得更多。大多数患者在每日15毫克的剂量时停止用药。副作用轻微。另一组10例长期左旋多巴治疗存在问题或当前治疗效果不佳的患者，用另一种麦角灵衍生物CU 32 - 085进行双盲交叉试验。剂量如第一个实验那样增加至每日20毫克。7例患者在使用活性药物期间病情改善。3例患者在活性期运动障碍加重，2例患者运动障碍改善。3例患者在使用活性药物期间发现明显的抗抑郁作用。5例患者表示在治疗活性期开/关现象略有减轻。似乎有必要对这些药物进行更广泛的研究。
